Patent · US Active

Aminoquinazoline compounds as A2A antagonist

US10138212B2 · kind B2 · utility

2Cited by

2References

18Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Amjad Ali · Freehold, US
Rongze Kuang · Green Brook, US
Yeon-Hee Lim · South San Francisco, US
Michael Man-Chu Lo · Rahway, US
Pauline C. Ting · New Providence, US
Purakkattle Biju · Piscataway, US
Manuel de Lera Ruiz · Readington, US
Sylvia Degrado · Scotch Plains, US
Alexander L. Tung · Bensalem, US
Timothy J. Henderson · Natick, US
Liwu Hong · Edison, US
Jae-Hun Kim · Scotch Plains, US
Dong Won-Shik Kim · Rockville, US
Joe F. Lee · Brooklyn, US
Jie Wu · Freeport, US
Heping Wu · Edison, US
Yushi Xiao · Rahway, US
Tao Yu · Shanghai, CN
Gang Zhou · Bound Brook, US
Xiaohong Zhu · Edison, US
Kevin D. McCormick · Berkeley Heights, US
Jayaram R. Tagat · Westfield, US
Dong Xiao · Hackettstown, US
Tanweer A. Khan · Bound Brook Junction, US
Jianhua Cao · Laishui, CN
Michael Y. Berlin · Flemington, US
Yonglian Zhang · Metuchen, US

Key dates

Filing date	Feb 1, 2016
Grant date	Nov 27, 2018
Priority date	—
Expiry date	Feb 1, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.